preclinics logotype

News feed

Get the latest updates in your mailbox by subscribing to our newsletter.

 
News item

UK B1.1.7 SARS-CoV-2 pseudoviruses

22/02/2021 **UK B1.1.7 SARS-CoV-2 pseudoviruses available for Neutralization assay: **Preclinics is offering its Customers the Pseudoviral Infection/Neutralization assay with recent mutated strain B1.1.7. (image: 21b-05-014_b117-infection.jpg) (image: pexels-cdc-3992933.jpg) Photo by CDC from Pexels
News item

SARS-CoV-2 and COVID-19 research

10/08/2020 preclinics is developing assays for SARS-CoV-2 and COVID-19 research. Now our virus neutralizing assays are available to test the neutralizing effect of antibodies and sera. Assays for protease inhibitors, as well as in vivo models in K18-huACE2 mice will follow soon. For covid19 research we have a lung inflammation model established. (image: noname015.jpg) More info…
News item

COVID-19 neutralization assay

27/11/2020 COVID-19 Pseudovirus Infection and Neutralisation Service Preclinics GmbH offers its customers Covid-19 pseudotyped viruses infection and neutralization services in vitro and ex vivo. This service is based on the crucial interaction of trimeric Spike protein of SARS-Cov2 with its eukaryotic counter receptor ACE2. This service can be used for: 1. Screening patient serum for neutralizing antibodies 2. Validating inhibitors of the Spike-ACE2 interaction 3. COVID-19 vaccine development **Assay lay out** (image: neutralization-assay-layout_small.jpg) More info…
News item

Nanobodies (Hybrid 2nd edition) 08-09 September 2021

25/08/2021 We look forward to welcoming you at the Nanobodies (Hybrid 2nd edition) Symposium on 08-09 September 2021 in Brussels. Let`s talk together about our services, products and common interests. For more information please click (link: https://www.vibconferences.be/events/nanobodies-hybrid-2nd-edition text: **nanobodies-hybrid-2nd-edition**) More info…